Bharat Biotech Expands Covaxin Production

Bharat Biotech International Ltd (BBIL), the Hyderabad-headquartered vaccine manufacturer has augmented its Covaxin-producing capacity to 500 million (50 crores) doses per year, BBIL has said on Sunday. The company has informed that it has supplied 20 million (2 crore) doses to what it termed as the national roll-out in last month.

“To our supporters and critics, ever since the start of the pandemic, team Bharat Biotech has been diligently developing Covaxin and scaling up manufacturing capacities to meet global and public health requirements,” the company’s MD Suchitra Ella tweeted.

She also stressed that the company’s Covaxin Covid-19 vaccine helps to neutralise the SARS-CoV-2 virus’ key emerging strains that include the double mutant of B.1.617 and B.1.1.7 identified in India and the United Kingdom respectively.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related News